Koshinski Asset Management
CRNX icon

Koshinski Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Koshinski Asset Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-225
Closed -$4.94K – 846
2022
Q1 		$4.94K Hold
225
– – ﹤0.01% 1791
2021
Q4 		$6.39K Buy
+225
New +$5.55K ﹤0.01% 1745

Other funds holding CRNX

DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Koshinski Asset Management's CRNX Position: Q2 2022 in Review

Koshinski Asset Management sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2022, closing a stake of 225 shares — an estimated $4.94K sold.

Koshinski Asset Management first reported a position in CRNX in Q4 2021 and held it in 2 quarters. The position peaked at $6.39K in Q4 2021. 111 funds tracked by Wall St. Rank hold CRNX as of Q2 2022.

  • Koshinski Asset Management reported no remaining Crinetics Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Koshinski Asset Management sold 225 Crinetics Pharmaceuticals shares in Q2 2022, an estimated $4.94K.
  • Koshinski Asset Management first reported a position in Crinetics Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Koshinski Asset Management's Crinetics Pharmaceuticals position peaked at $6.39K in Q4 2021.
  • 111 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2022.

Based on Koshinski Asset Management's 13F filing for Q2 2022, filed 12 Jul 2022.